{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:46:06Z","timestamp":1793947566531,"version":"4.8.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01533-8","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T22:57:09Z","timestamp":1745794629000},"page":"435-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity"],"prefix":"10.1007","volume":"43","author":[{"given":"Arun A.","family":"Azad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Gurney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Voskoboynik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Perabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"9360","key":"1533_CR1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","volume":"361","author":"H Gr\u00f6nberg","year":"2003","unstructured":"Gr\u00f6nberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859\u2013864. https:\/\/doi.org\/10.1016\/S0140-6736(03)12713-4","journal-title":"Lancet"},{"issue":"6","key":"1533_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, Buckley DI, Griffin JC, Cookson MS (2023) Updates to advanced prostate cancer: AUA\/SUO guideline. J Urol 209(6):1082\u20131090. https:\/\/doi.org\/10.1097\/JU.0000000000003452","journal-title":"J Urol"},{"issue":"10","key":"1533_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, D\u2019Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA (2023) Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(10):1067\u20131096. https:\/\/doi.org\/10.6004\/jnccn.2023.0050","journal-title":"J Natl Compr Canc Netw"},{"key":"1533_CR4","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, Chen Z, Zhao SC (2023) Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Update 68:100962. https:\/\/doi.org\/10.1016\/j.drup.2023.100962","journal-title":"Drug Resist Update"},{"issue":"3","key":"1533_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/cancers16030663","volume":"16","author":"QH Chen","year":"2024","unstructured":"Chen QH, Erick Munoz E, Ashong D (2024) Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer. Cancers (Basel) 16(3):663. https:\/\/doi.org\/10.3390\/cancers16030663","journal-title":"Cancers (Basel)"},{"key":"1533_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","volume":"31","author":"M Pettersson","year":"2019","unstructured":"Pettersson M, Crews CM (2019) PROteolysis targeting chimeras (PROTACs) - past, present and future. Drug Discov Today Technol 31:15\u201327. https:\/\/doi.org\/10.1016\/j.ddtec.2019.01.002","journal-title":"Drug Discov Today Technol"},{"key":"1533_CR7","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/med.21877","volume":"42","author":"S He","year":"2022","unstructured":"He S, Dong G, Cheng J, Wu Y, Sheng C (2022) Strategies for designing proteolysis targeting chimeras (PROTACs). Med Res Res 42:1280\u20131342. https:\/\/doi.org\/10.1002\/med.21877","journal-title":"Med Res Res"},{"issue":"2","key":"1533_CR8","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai AC, Crews CM (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 16(2):101\u2013114. https:\/\/doi.org\/10.1038\/nrd.2016.211","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1533_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1021\/acs.jmedchem.7b00168","volume":"61","author":"N Shibata","year":"2018","unstructured":"Shibata N, Nagai K, Morita Y, Ujikawa O, Ohoka N, Hattori T, Koyama R, Sano O, Imaeda Y, Nara H, Cho N, Naito N (2018) Development of protein degradation inducers of androgen receptor by conjugation of androgen receptor ligands and inhibitor of apoptosis protein ligands. J Med Chem 61(2):543\u2013575. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00168","journal-title":"J Med Chem"},{"issue":"2","key":"1533_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","volume":"62","author":"X Han","year":"2019","unstructured":"Han X, Wang C, Qin C, Xiang W, Fernandez-Salas E, Yang CY, Wang M, Zhao L, Xu T, Chinnaswamy K, Delproposto J, Stuckey J, Wang S (2019) Discovery of ard-69 as a highly potent proteolysis targeting chimera (Protac) degrader of androgen receptor (AR) for the treatment of prostate cancer. J Med Chem 62(2):941\u2013964. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01631","journal-title":"J Med Chem"},{"key":"1533_CR11","doi-asserted-by":"publisher","first-page":"114112","DOI":"10.1016\/j.biopha.2022.114112","volume":"158","author":"X Jia","year":"2023","unstructured":"Jia X, Han X (2023) Targeting androgen receptor degradation with PROTACs from bench to bedside. Biomed Pharmacother 158:114112. https:\/\/doi.org\/10.1016\/j.biopha.2022.114112","journal-title":"Biomed Pharmacother"},{"issue":"13","key":"1533_CR12","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1039\/d1cs00762a","volume":"51","author":"Y Chen","year":"2022","unstructured":"Chen Y, Tandon I, Heelan W, Wang Y, Tang W, Hu Q (2022) Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation. Chem Soc Rev 51(13):5330\u20135350. https:\/\/doi.org\/10.1039\/d1cs00762a","journal-title":"Chem Soc Rev"},{"key":"1533_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00029","volume":"1","author":"W Abida","year":"2017","unstructured":"Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S, McLaughlin B, Curtis K, Hyman DM, Durack JC, Solomon SB, Arcila ME, Zehir A, Syed A, Gao J, Chakravarty D, Vargas HA, Robson ME, Joseph V, Offit K, Donoghue MTA, Abeshouse AA, Kundra R, Heins ZJ, Penson AV, Harris C, Taylor BS, Ladanyi M, Mandelker D, Zhang L, Reuter VE, Kantoff PW, Solit DB, Berger MF, Sawyers CL, Schultz N, Scher HI (2017) Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making. JCO Precis Oncol PO.17.00029. JCO Precis Oncol 1:1. https:\/\/doi.org\/10.1200\/PO.17.00029","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"1533_CR14","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1080\/14728222.2023.2293757","volume":"27","author":"J Wang","year":"2023","unstructured":"Wang J, Ben-David R, Mehrazin R, Yang W, Tewari AK, Kyprianou N (2023) Novel signatures of prostate cancer progression and therapeutic resistance. Expert Opin Ther Targets 27(12):1195\u20131206. https:\/\/doi.org\/10.1080\/14728222.2023.2293757","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"1533_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10555-024-10168-9","volume":"43","author":"M Ashrafizadeh","year":"2024","unstructured":"Ashrafizadeh M, Zhang W, Tian Y, Sethi G, Zhang X, Qiu A (2024) Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation. Cancer Metastasis Rev 43(1):229\u2013260. https:\/\/doi.org\/10.1007\/s10555-024-10168-9","journal-title":"Cancer Metastasis Rev"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01533-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01533-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:39:47Z","timestamp":1746178787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01533-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1533"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01533-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study (ClinicalTrials.gov Identifier: NCT05252364) was performed in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. The protocol was approved by an Institutional Review Board at each investigative site, and all patients provided written informed consent before any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study oversight"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}